Superworth

Lemaitre Vascular price to free cash flow LMAT

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Nov 2, 2026
25.2×
8-year median
41.2×
Against its 8-year history
7th
percentile: 0 is its lowest day, 100 its highest
8-year range
4.8× to 83.4×
Peer median
22.4×

Lemaitre Vascular's price to free cash flow is 25.2× as of Nov 2, 2026.

That is below its 8-year median of 41.2×, lower than on 93% of days in the last 8 years.

Over that time it ranged from 4.8× in Mar 2020 to 83.4× in Jun 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 22.4×.

Price to free cash flow over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far25.2×24.4×35.1×
202528.7×28.4×66.8×
202462.3×47.9×72.5×
202355.3×42.1×83.4×
202242.6×23.1×43.6×
202128.3×26.4×45.3×
202035.7×4.8×57.1×
20196.3×6.0×61.2×
201828.2×26.8×41.0×
2017n/m a value too high to mean anything
201633.7×23.7×33.7×
201537.9×29.4×45.9×
201442.1×39.1×84.4×
201378.0×26.3×98.9×
201234.2×18.1×37.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Lemaitre Vascular's size, closest first, today.

CompanyPrice to free cash flow
LMATLemaitre Vascular25.2×
INSPInspire Medical Systems16.6×
UFPTUFP Technologiesn/m
EYENational Vision27.6×
CDRECadre17.3×
STAAStaar Surgicaln/m
WRBYWarby Parker136×
ATRCAtriCure57.3×
BVSBioventus11.7×
IARTIntegra Lifesciences12.3×
IRMDIradimed38.9×
Peer median22.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lemaitre Vascular

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.